COMMUNIQUÉS West-GlobeNewswire

AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering
22/05/2024
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering Strategic partnership provides a seamless one-stop-shop for [...]
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
22/05/2024
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta [...]
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
22/05/2024
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Mersana Therapeutics to Present at Upcoming Investor Conferences
22/05/2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
22/05/2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May [...]
Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause
22/05/2024
NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 ( [...]
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
22/05/2024
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on [...]
Soleno Therapeutics to Participate in Upcoming Investor Conferences
22/05/2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn and Rajiv Panwar
22/05/2024
Joe Senn, PhD, joins as SVP of Nonclinical Research & Development Rajiv Panwar, PhD, joins as VP and Head of Chemistry, Manufacturing, and Controls Appointments strengthen Oruka’s executive leadership team and [...]
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
22/05/2024
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
MediWound to Report First Quarter 2024 Financial Results
22/05/2024
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic [...]
Alignment Healthcare to Present at William Blair's 44th Annual Growth Stock Conference
22/05/2024
ORANGE, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will present at William Blair's [...]
NeurAxis Reports First Quarter 2024 Financial Results
22/05/2024
CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
22/05/2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International [...]
Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
22/05/2024
Presentations include late-breaking abstract highlighting preliminary results from Phase 2 study of BJT-778 in chronic hepatitis D (CHD) SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today [...]
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
22/05/2024
Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened [...]
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
22/05/2024
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations. More mature interim data to be presented at EASL following abstract data cuts earlier in the [...]
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
22/05/2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
22/05/2024
First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systems Investigational package of broad immune agonists derived from Gram-negative bacteria which induces [...]

Pages